Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25316116 | 0.87 | AOC3 (0.44) | AOC3MAPTKMT2AHRH3 | |
| SCHEMBL13355127 | 0.87 | AOC3 (0.44) | AOC3HRH3 | |
| SCHEMBL30507225 | 0.87 | AOC3 (0.44) | AOC3MAPTKMT2AHRH3 | |
| SCHEMBL16519571 | 0.86 | AOC3 (0.43) | AOC3HRH3 | |
| SCHEMBL26022328 | 0.85 | TP53 (0.45) | AOC3HRH3TP53 | |
| SCHEMBL13354899 | 0.83 | OPRK1 (0.44) | AOC3 | |
| SCHEMBL13355130 | 0.80 | KDM4E (0.54) | MEN1NPC1ALDH1A1GAAKMT2A | |
| SCHEMBL30021259 | 0.80 | METAP1 (0.50) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL8222715 | 0.80 | METAP1 (0.50) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL29289829 | 0.79 | ALPI (0.41) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |